Longeveron inc.LGVN.US Overview

US StockHealthcare

(No presentation for LGVN)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

LGVN Overall Performance

LGVN AI Analysis & Strategy

LGVN Recent Performance

3.06%

Longeveron inc.

0.81%

Avg of Sector

-1.14%

S&P500

LGVN PowerScanner

LGVN Key Information

LGVN Valuation Metrics

LGVN Earnings Table

LGVN Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.